摘要
Anticoagulationisimperativetoreducetheincidenceofthromboticcomplicationsinpatientsundergoingpercutaneousinterventionalcardiovascularprocedures;however,thisisattheexpenseofincreasedriskofbleeding.Theoptimalanticoagulationstrategyfortheseproceduresremainsunclear.Unfractionatedheparinisthemostcommonlyusedanticoagulantduringinterventionalprocedures,buthasseverallimitations,suchasrelativelyhighincidenceofbleedingevents,occurrenceofheparin-inducedthrombocytopenia,andaparadoxicalthromboticeffect.Contemporarystudieshavedemonstratedthatbivalirudindecreasestheoccurrenceofbleedingcomplications,butpotentiallyincreasestheriskofacutestentthrombosis.Thisreviewdiscussesthepharmacologyofbivalirudinanditscurrentclinicalapplicationinpatientsundergoingpercutaneouscoronaryinterventionandtranscatheteraorticvalvereplacementprocedures.
出版日期
2018年03月04日（中国期刊网平台首次上网日期，不代表论文的发表时间）
